Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJBO3D)

• Drug Name: 2-Sulfhydryl-Ethanol Drug Info
• Synonyms: beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Beta-Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1567
  ChEBI ID: CHEBI:41218
  CAS Number: CAS 60-24-2
  TTD Drug ID: DMJBO3D

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[6]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[7]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[8]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[9]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[10]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[10]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[11]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[12]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[13]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[14]

Drug(s) Targeting Delta-aminolevulinic acid dehydratase (ALAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[15]
Porphobilinogen	DM5HMTB	N. A.	N. A.	Phase 2	[1]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
S,S-(2-Hydroxyethyl)Thiocysteine	DMLPAD8	Discovery agent	N.A.	Investigative	[1]
Delta-Amino Valeric Acid	DMV7IAK	Discovery agent	N.A.	Investigative	[1]
4,7-Dioxosebacic Acid	DML5302	Discovery agent	N.A.	Investigative	[1]
Laevulinic Acid	DMTZ17V	Discovery agent	N.A.	Investigative	[1]
3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid	DMQXPM3	Discovery agent	N.A.	Investigative	[1]
5-Fluorolevulinic Acid	DMDV48S	Discovery agent	N.A.	Investigative	[1]
4-Oxosebacic Acid	DMADSUY	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Alpha-1-antitrypsin (SERPINA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glassia	DM83MOK	Emphysema	CA21	Approved	[16]
Zemaira	DMA5QPM	Emphysema	CA21	Approved	[17]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[18]
AGTC-0106	DMMKASG	Alpha-1 antitrypsin deficiency	5C5A	Phase 2	[19]

Drug(s) Targeting Fibroblast growth factor-2 (FGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucralfate	DMP9HBO	Acne vulgaris	ED80	Approved	[20]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[21]
DVC1-0101	DMUGBQK	Arteriosclerosis	BD40	Phase 2	[22]
Bemarituzumab	DMWNYIE	Gastric adenocarcinoma	2B72	Phase 2	[23]
FPA144	DM1EBRK	Bladder cancer	2C94	Phase 1	[24]
TGP-580	DMYN6G0	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 2	[25]
RG-8803	DMI0CYV	Diabetic retinopathy	9B71.0	Terminated	[26]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[1]
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[27]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	DM9KUQZ	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Hydroxysteroid dehydrogenase 3-beta (HSD3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-ANDROSTENE-3-17-DIONE	DMSE8NU	Discovery agent	N.A.	Investigative	[1]
Equilenin	DMHO56W	Discovery agent	N.A.	Investigative	[1]
5alpha-Androstan-3,17-Dione	DMHI7Y2	Discovery agent	N.A.	Investigative	[1]
4-MA	DMNCVIP	Discovery agent	N.A.	Investigative	[28]
17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)	DMDR1M6	Discovery agent	N.A.	Investigative	[29]
Epostane	DMV8PB4	Abortion	JA00	Investigative	[30]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[31]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[32]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[33]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[14]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[34]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[14]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[35]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[36]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[34]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[37]

Drug(s) Targeting M-phase inducer phosphatase 2 (MPIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[38]
MX-7065	DMP26BW	Solid tumour/cancer	2A00-2F9Z	Terminated	[39]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
Cysteinesulfonic Acid	DMXI8FP	Discovery agent	N.A.	Investigative	[1]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[2]
3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	DMJZEMB	Discovery agent	N.A.	Investigative	[40]
4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	DMQA0EJ	Discovery agent	N.A.	Investigative	[40]
ADOCIAQUINONE B	DMPOU86	Discovery agent	N.A.	Investigative	[41]
3-isopropyl-4-phenylnaphthalene-1,2-dione	DMYZCWX	Discovery agent	N.A.	Investigative	[40]
4-ethoxynaphthalene-1,2-dione	DMUN7KC	Discovery agent	N.A.	Investigative	[38]

Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[43]
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[44]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[45]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[46]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[47]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[48]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[49]
Nolatrexed	DMOF0CA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[50]
Plevitrexed (R)-isomer	DMTL39C	Gastric adenocarcinoma	2B72	Phase 2	[51]

Drug(s) Targeting Lactoylglutathione lyase (GLO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[52]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[52]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[52]
S-(N-butyl-N-hydroxycarbamoyl)glutathione	DMU7EQV	Discovery agent	N.A.	Investigative	[53]
S-(N-heptyl-N-hydroxycarbamoyl)glutathione	DMV6T1Q	Discovery agent	N.A.	Investigative	[53]
S-(N-propyl-N-hydroxycarbamoyl)glutathione	DMRFKZ6	Discovery agent	N.A.	Investigative	[53]
S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione	DM1AHIW	Discovery agent	N.A.	Investigative	[2]
S-(N-pentyl-N-hydroxycarbamoyl)glutathione	DM4E9J2	Discovery agent	N.A.	Investigative	[53]
S-(N-methyl-N-hydroxycarbamoyl)glutathione	DM1C9W3	Discovery agent	N.A.	Investigative	[53]
S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione	DM3FXPV	Discovery agent	N.A.	Investigative	[53]

Drug(s) Targeting Plasmodium Adenylosuccinate synthetase (Malaria Adss)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanosine-5'-Diphosphate	DM0MUKQ	Discovery agent	N.A.	Investigative	[1]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[1]
Diphosphate	DMHY30B	Discovery agent	N.A.	Investigative	[1]
6-Cl-IMP	DMNTDFV	Discovery agent	N.A.	Investigative	[54]
(Carboxyhydroxyamino)Ethanoic Acid	DMZB0C3	Discovery agent	N.A.	Investigative	[1]
(C8-R)-Hydantocidin 5'-Phosphate	DM5WH6R	Discovery agent	N.A.	Investigative	[1]
(C8-S)-Hydantocidin 5'-Phosphate	DMMH179	Discovery agent	N.A.	Investigative	[1]
6-O-Phosphoryl Inosine Monophosphate	DM6YHBR	Discovery agent	N.A.	Investigative	[1]
Hydantocidin-5'-Monophosphate	DMOTXP1	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Polypeptide deformylase (PDF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[55]
Meprobamate	DMHM93Y	Anxiety		Approved	[56]
Pralatrexate	DMAO80I	Breast cancer	2C60-2C65	Approved	[57]
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[58]
Trimetrexate	DMDEA85	Toxoplasmosis	1F57	Approved	[59]
MCB-3837	DM0R4Z5	Malaria	1F40-1F45	Approved	[56]
Chlorproguanil	DM1IFGT	Malaria	1F40-1F45	Approved	[56]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[60]
Metoprine	DM5GQD7	Advanced cancer	2A00-2F9Z	Phase 2	[61]
Aminopterin	DMQ9RBV	leukaemia	2A60-2B33	Withdrawn from market	[43]

Drug(s) Affected By Superoxide dismutase (SOD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[62]
Haloperidol	DM96SE0	Delirium		Approved	[63]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[64]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[67]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[71]

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Selenium	DM25CGV	N. A.	N. A.	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[74]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[75]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[76]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[77]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[78]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[82]
Selenium	DM25CGV	N. A.	N. A.	Approved	[83]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[84]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[85]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[90]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-1-antitrypsin (SERPINA1)	TTA7UJC	A1AT_HUMAN	Inhibitor	[2]
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[1]
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[1]
Delta-aminolevulinic acid dehydratase (ALAD)	TTJHKYD	HEM2_HUMAN	Inhibitor	[1]
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Inhibitor	[1]
High mobility group protein B1 (HMGB1)	TTWQYB7	HMGB1_HUMAN	Inhibitor	[1]
Hydroxysteroid dehydrogenase 3-beta (HSD3B)	TTZT9R2	3BHS1_HUMAN; 3BHS2_HUMAN	Inhibitor	[1]
Lactoylglutathione lyase (GLO1)	TTV9A7R	LGUL_HUMAN	Inhibitor	[2]
M-phase inducer phosphatase 2 (MPIP2)	TTR0SWN	MPIP2_HUMAN	Inhibitor	[1]
Plasmodium Adenylosuccinate synthetase (Malaria Adss)	TTYQ4AE	PURA_PLAFA	Inhibitor	[1]
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Post-Translational Modifications	[3]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Gene/Protein Processing	[4]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Gene/Protein Processing	[5]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [3] Modification of cysteine 111 in Cu/Zn superoxide dismutase results in altered spectroscopic and biophysical properties. Protein Sci. 2004 May;13(5):1347-55. doi: 10.1110/ps.03576904.
• [4] Thiol modulation of TNF alpha and IL-1 induced MnSOD gene expression and activation of NF-kappa B. Mol Cell Biochem. 1995 Jul 5;148(1):45-57. doi: 10.1007/BF00929502.
• [5] Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol. 1995 Nov;269(5 Pt 1):L588-602. doi: 10.1152/ajplung.1995.269.5.L588.
• [6] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [7] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [8] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [9] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [10] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [11] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [12] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [13] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [14] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [15] Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9.
• [16] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [18] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [19] First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9.
• [20] Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
• [21] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [22] DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
• [26] US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
• [27] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [28] Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin. Skin Pharmacol. 1997;10(3):160-8.
• [29] Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment Anticancer Res. 1995 Jul-Aug;15(4):1349-54.
• [30] Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med. 1988 Sep 29;319(13):813-7.
• [31] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [32] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [33] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [34] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [35] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [36] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [37] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [38] Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
• [39] Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
• [40] Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
• [41] Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
• [42] The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
• [43] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [44] Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
• [45] Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
• [46] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
• [47] DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
• [48] Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
• [49] Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
• [50] A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
• [51] Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
• [52] Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
• [53] Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
• [54] High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants. Biol Reprod. 1994 Jun;50(6):1403-12.
• [55] Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
• [56] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [57] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [58] Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
• [59] Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
• [60] Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
• [61] Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
• [62] Poly(ADP-ribose) polymerase 1 contributes to oxidative stress through downregulation of sirtuin 3 during cisplatin nephrotoxicity. Anat Cell Biol. 2016 Sep;49(3):165-176. doi: 10.5115/acb.2016.49.3.165. Epub 2016 Sep 29.
• [63] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [64] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [65] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [66] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [67] Inactivation of cytochrome c oxidase by mutant SOD1s in mouse motoneuronal NSC-34 cells is independent from copper availability but is because of nitric oxide. J Neurochem. 2010 Jan;112(1):183-92. doi: 10.1111/j.1471-4159.2009.06441.x. Epub 2009 Oct 20.
• [68] Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain. 2006 Jul;129(Pt 7):1693-709. doi: 10.1093/brain/awl118. Epub 2006 May 15.
• [69] Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
• [70] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [71] Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther. 2005 Sep;4(9):949-55.
• [72] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [73] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [74] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [75] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [76] Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
• [77] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [78] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [79] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [80] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [81] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [82] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [83] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [84] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [85] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [86] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [87] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [88] Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
• [89] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [90] Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.